Logo image of APUS

APIMEDS PHARMACEUTICALS US I (APUS) Stock Overview

NYSEARCA:APUS - US03771D1028 - Common Stock

1.83 USD
-0.03 (-1.61%)
Last: 8/29/2025, 8:06:40 PM

APUS Key Statistics, Chart & Performance

Key Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap23.02M
Shares12.58M
Float3.09M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)N/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO05-09 2025-05-09
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


APUS short term performance overview.The bars show the price performance of APUS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10

APUS long term performance overview.The bars show the price performance of APUS in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of APUS is 1.83 USD. In the past month the price increased by 5.17%.

APIMEDS PHARMACEUTICALS US I / APUS Daily stock chart

APUS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.68B
AMGN AMGEN INC 13.19 154.89B
GILD GILEAD SCIENCES INC 14.6 140.17B
VRTX VERTEX PHARMACEUTICALS INC 23.08 100.25B
REGN REGENERON PHARMACEUTICALS 12.72 61.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.53B
ARGX ARGENX SE - ADR 76.83 43.59B
ONC BEONE MEDICINES LTD-ADR 6.16 36.38B
INSM INSMED INC N/A 28.77B
BNTX BIONTECH SE-ADR N/A 24.04B
NTRA NATERA INC N/A 23.09B
BIIB BIOGEN INC 8.26 19.38B

About APUS

Company Profile

APUS logo image Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.

Company Info

APIMEDS PHARMACEUTICALS US I

100 Matawan Road, Suite 325

Matawan NEW JERSEY US

Employees: 2

APUS Company Website

Phone: 18482015010

APIMEDS PHARMACEUTICALS US I / APUS FAQ

What is the stock price of APIMEDS PHARMACEUTICALS US I today?

The current stock price of APUS is 1.83 USD. The price decreased by -1.61% in the last trading session.


What is the ticker symbol for APIMEDS PHARMACEUTICALS US I stock?

The exchange symbol of APIMEDS PHARMACEUTICALS US I is APUS and it is listed on the NYSE Arca exchange.


On which exchange is APUS stock listed?

APUS stock is listed on the NYSE Arca exchange.


What is APIMEDS PHARMACEUTICALS US I worth?

APIMEDS PHARMACEUTICALS US I (APUS) has a market capitalization of 23.02M USD. This makes APUS a Nano Cap stock.


How many employees does APIMEDS PHARMACEUTICALS US I have?

APIMEDS PHARMACEUTICALS US I (APUS) currently has 2 employees.


What are the support and resistance levels for APIMEDS PHARMACEUTICALS US I (APUS) stock?

APIMEDS PHARMACEUTICALS US I (APUS) has a support level at 1.82. Check the full technical report for a detailed analysis of APUS support and resistance levels.


Should I buy APIMEDS PHARMACEUTICALS US I (APUS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does APIMEDS PHARMACEUTICALS US I (APUS) stock pay dividends?

APUS does not pay a dividend.


What is the Short Interest ratio of APIMEDS PHARMACEUTICALS US I (APUS) stock?

The outstanding short interest for APIMEDS PHARMACEUTICALS US I (APUS) is 0.95% of its float. Check the ownership tab for more information on the APUS short interest.


APUS Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to APUS.


Chartmill TA Rating
Chartmill Setup Rating

APUS Financial Highlights


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A

APUS Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

APUS Ownership

Ownership
Inst OwnersN/A
Ins Owners14.44%
Short Float %0.95%
Short Ratio0.21